Marshall Wace LLP bought a new position in Rezolute, Inc. (NASDAQ:RZLT – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,047,230 shares of the company’s stock, valued at approximately $4,503,000. Marshall Wace LLP owned 2.61% of Rezolute at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in RZLT. Virtu Financial LLC bought a new position in shares of Rezolute during the first quarter worth about $37,000. Jeppson Wealth Management LLC bought a new position in Rezolute in the 2nd quarter worth about $45,000. XTX Topco Ltd grew its position in Rezolute by 205.8% in the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Rezolute in the first quarter valued at approximately $229,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Rezolute during the second quarter valued at approximately $255,000. 82.97% of the stock is owned by institutional investors and hedge funds.
Rezolute Price Performance
Shares of RZLT opened at $4.59 on Wednesday. Rezolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10. The stock has a market capitalization of $184.22 million, a P/E ratio of -4.03 and a beta of 1.18. The firm’s 50 day moving average is $4.64 and its 200-day moving average is $3.89.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the company. Maxim Group raised their target price on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, August 6th. Craig Hallum began coverage on Rezolute in a report on Tuesday, June 4th. They set a “buy” rating and a $14.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Guggenheim initiated coverage on shares of Rezolute in a research report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a report on Friday, September 27th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $11.57.
Check Out Our Latest Stock Analysis on RZLT
About Rezolute
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Further Reading
- Five stocks we like better than Rezolute
- What is the Dogs of the Dow Strategy? Overview and Examples
- Why Lennar Stock Could Be the Best Play in the Housing Market
- The How and Why of Investing in Gold Stocks
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How to Plot Fibonacci Price Inflection Levels
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.